Related Experiment Video
Updated: Jul 7, 2025
03:20
Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
Published on: September 22, 2023
1.7K
[Lower gastrointestinal dysfunction in patients with Parkinson's disease]
A A Pilipovich1, O V Vorob'eva1, S A Makarov1
1Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|December 26, 2023
Summary
Most Parkinson's disease (PD) patients experience lower gastrointestinal tract dysfunction, primarily constipation. This dysfunction is linked to motor and non-motor symptoms, but not directly to dopaminergic therapy.
Area of Science:
- Neurology
- Gastroenterology
Context:
- Parkinson's disease (PD) is a neurodegenerative disorder affecting motor function.
- Gastrointestinal (GI) dysfunction is a common non-motor symptom in PD patients.
- Understanding the prevalence and associations of lower GI dysfunction is crucial for patient management.
Purpose:
- To evaluate the lower gastrointestinal tract dysfunction in Parkinson's disease (PD) patients.
- To explore the relationship between GI dysfunction and motor and non-motor symptoms in PD.
Summary:
- 71.2% of PD patients (Hoehn and Yahr stages I-III) reported constipation, while 27.9% experienced diarrhea.
- Constipation correlated with age, PD severity (H&Y stage, UPDRS), motor symptoms, and affective/autonomic disorders.
- Diarrhea was linked to constipation severity and other GI issues, but not directly to PD stage or core symptoms; dopaminergic therapy showed no effect.
Impact:
- Highlights the high prevalence of lower GI dysfunction in early-stage PD.
- Suggests non-dopaminergic pathways and comorbidities contribute to PD-related bowel issues.
- Informs clinical practice regarding the assessment and management of GI symptoms in Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
274
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
274
01:15Parkinson's Disease: Overview
554
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
554
01:20Gastrointestinal Motility Disorders
381
Gastrointestinal or GI motility disorders are characterized by irregular gastrointestinal tract movements, disrupting food transit from the mouth to the anus. They are caused by damage or dysfunction in gut muscles or nerves. These disorders can cause symptoms such as severe constipation, diarrhea, abdominal pain, and swallowing difficulties. Disorders can affect any segment of the GI tract and range widely in severity, from common conditions like GERD to life-threatening conditions like...
381
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
332
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
332
01:25Factors Influencing Drug Absorption: Disease States and Pharmacology
523
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
523
01:37Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K